Clinical trials: psoriasis
Epidermolysis Bullosa, Ichthyosis
Thera-Clean® Microbubbles System in Patients With Skin Diseases
Thera-Clean® Microbubble has proved to improve skin conditions in animals, however little research has been done regarding human subjects.
- Conditions
- Epidermolysis Bullosa, Ichthyosis, Atopic Dermatitis, Psoriasis
- Trial name
- NCT07050810
- Testing
- TheraClean
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Psoriasis
A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque Psoriasis
The goal of this investigator-initiated, real-world, observational study is to investigate the impact of weight loss on treatment efficacy in overweight or obese Chinese patients with moderate-to-severe plaque psoriasis.
- Trial name
- NCT07382388
- Testing
- Weight loss and psoriasis treatment, psoriasis treatment
- Volunteers
- 70 people
- Sponsor
- Peking University Third Hospital
Plaque Psoriasis
Treatment of Moderate to Severe Plaque Psoriasis
To assess the efficacy and safety of TQH3906 in subjects with moderate to severe plaque psoriasis, as well as the PK and PD characteristics of multiple doses
- Trial name
- NCT06542614
- Testing
- TQH3906 capsules
- Where
- 35 sites in China
- Volunteers
- 209 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Psoriasis
Combined Use of Cyclosporine and Metformin in Treatment of Psoriasis vs Cyclosporine Alone
This study is a comparative clinical study evaluating the efficacy of combined therapy using cyclosporine and metformin versus cyclosporine alone in the treatment of psoriasis.
- Trial name
- CsA/Met (NCT07375654)
- Testing
- Cyclosporin (CSA), Metformin (500 mg Twice a day)
- Where
- Egypt
- Volunteers
- 32 people
- Sponsor
- Cairo University
Moderate to Severe Plaque Psoriasis
A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis
This is a clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and immunogenicity of SHR-1139 injection in healthy subjects who receive a single subcutaneous injection or intravenous infusion of…
- Trial name
- NCT07051538
- Testing
- SHR-1139 Injections
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Plaque Psoriasis
Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia
The aim is to evaluate the safety and efficacy of vunakizumab combined with recaticimab versus vunakizumab combined with placebo in the treatment of plaque psoriasis with dyslipidemia.
- Trial name
- NCT07373847
- Testing
- vunakizumab and recaticimab.
- Volunteers
- 40 people
- Sponsor
- Xiangya Hospital of Central South University
Nail Psoriasis, Nail Damage
Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis
A randomized, double blind, placebo-controlled, unicenter, parallel group study to assess the efficacy, safety and tolerability of a multi-funtion toe nail patch in patients affected by nail fragility, nail mychosis and psoriasis…
- Conditions
- Nail Psoriasis, Nail Damage, Mycosis
- Trial name
- NCT07029516
- Testing
- Cosmetic patch containing urea applicated daily for 3 months
- Where
- Italy
- Volunteers
- 72 people
- Sponsor
- Wooshin Labottach Co., Ltd.
Psoriasis
A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis
The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment until week 20 and respond with a Psoriasis Area and Severity Index score (PASI) =…
- Trial name
- GUIDE (NCT03818035)
- Testing
- Guselkumab
- Where
- 90 sites in France, Germany
- Volunteers
- 880 people
- Sponsor
- Janssen-Cilag International NV
Psoriasis
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
Psoriasis is one of the commonest and most researched chronic immune-mediated inflammatory skin disorders that affects approximately 1-3% of the population worldwide and significantly impairs patients' quality of life.
- Trial name
- NCT06050330
- Testing
- skin biopsy
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Sohag University
Post-Acute COVID-19 Syndrome, ME/CFS
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related…
- Conditions
- Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA)
- Trial name
- NCT04806620
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Brain Inflammation Collaborative
Moderate to Severe Plaque Psoriasis
To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled study in subjects with moderate to severe plaque psoriasis.
- Trial name
- SOLARES-PsO-1 (NCT04566666)
- Testing
- SCD-044_Low Dose (Dose 1), SCD-044_Intermediate Dose (Dose 2), SCD-044_High Dose (Dose 3)
- Where
- 50 sites in United States, El Salvador and 3 more
- Volunteers
- 263 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriasis (PsO), Traditional Chinese Medicine (TCM)
Research on the Extraction of Tongue and Facial Diagnosis Features of Psoriasis Vulgaris in Traditional Chinese Medicine and Its Correlation With Laboratory Indicators
Psoriasis Vulgaris is a chronic, inflammatory, and immune-activated skin disease. It is the most common type of psoriasis, accounting for approximately 85-90% of all psoriasis patients.
- Conditions
- Psoriasis (PsO), Traditional Chinese Medicine (TCM), Diagnosis
- Trial name
- NCT07351448
- Testing
- No intervention
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Shanghai Yueyang Integrated Medicine Hospital
Psoriasis, Atopic Dermatitis
LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice
This multicenter retrospective observational registry study will collect existing clinical data from Italian centers to describe epidemiology, treatment patterns, clinical evolution, safety, and comorbidities in patients aged 12…
- Conditions
- Psoriasis, Atopic Dermatitis, Vitiligo, Alopecia Areata
- Trial name
- LANDSCAPE (NCT07336641)
- Testing
- Conventional Systemic Therapies, Biologic Therapies
- Where
- Italy
- Volunteers
- 20,000 people
- Sponsor
- Fondazione ISIDE
Chronic Plaque Psoriasis
To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital
This study aims to compare efficacy of methotrexate vs apremilast in the management of chronic plaque psoriasis.Given the high prevalence of psoriasis in Pakistan and the significant psychological impact on patients, particularly…
- Trial name
- NCT07337434
- Testing
- Methotrexate, Apremilast
- Where
- Pakistan
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Syeda Sana Zaman
Psoriasis, Gluten Sensitivity
Dietary Approach to Mild-to-moderate Psoriasis
Psoriasis is a systemic chronic inflammatory immune-mediated disease whose etiopathogenetic mechanisms involve genetic predisposition, and immunological and environmental factors.
- Trial name
- NCT05644782
- Testing
- Open wheat challenge
- Where
- 3 sites in Italy
- Volunteers
- 82 people
- Sponsor
- University of Palermo
Psoriatic Arthritis, Psoriasis
Assessment of Fatigue in Psoriatic Arthritis and Cutaneous Psoriasis Patients
Psoriatic arthritis is characterized with pain, swelling and joint stiffness. These are inflammatory reactions against tendons, ligaments and joints associated with fatigue.
- Trial name
- RPso-Fatigue (NCT06101706)
- Testing
- Fatigue assessment, Quality of life assessment, Assess severity of psoriatic arthritis
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Centre Hospitalier Henri Duffaut - Avignon
Plaque Psoriasis, Psoriatic Arthritis
A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of TA-650 at increased dose of 10 mg/kg every 8 weeks in patients with psoriasis in whom effect of the treatment was confirmed after the treatment…
- Conditions
- Plaque Psoriasis, Psoriatic Arthritis, Pustular Psoriasis (Excluding a Localized), Psoriatic Erythroderma
- Trial name
- NCT01680159
- Testing
- TA-650
- Where
- 7 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Tanabe Pharma Corporation
Nail Psoriasis
An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis
. An open label proof of concept study will be conducted to assess the efficacy and safety of deucravactinib for treatment of nail psoriasis.
- Trial name
- NCT05124080
- Testing
- Deucravacitinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Psoriasis Vulgaris
Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris
Psoriasis is a common immune-mediated inflammatory skin disease affecting at least 100 million individuals worldwide. In Egypt, the prevalence of psoriasis ranges between 0.19% and 3% of the Egyptian people.
- Trial name
- NCT07320872
- Testing
- vaspin gene polymorphism
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Aswan University
Plaque Psoriasis
A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)
The study aims to evaluate the clinical efficacy of oral apremilast 30 mg BID compared with placebo in Chinese participants with moderate to severe PsO
- Trial name
- ESSENCE (NCT06122649)
- Testing
- apremilast
- Where
- 21 sites in China
- Volunteers
- 203 people
- Sponsor
- Amgen